Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection

Despite clinical guidelines classifying T2 rectal cancer as a contraindication for transanal local excision attributable to unacceptably high rates of local recurrence, it is a practice that persists clinically. Recent clinical trials have suggested that transanal local excision in addition to neoadjuvant chemoradiation is an acceptable alternative in select patients.

Source: Surgery - March 19, 2019 Category: Surgery Authors: Oliver K. Jawitz, Mohamed A. Adam, Megan C. Turner, Brian F. Gilmore, John Migaly Source Type: research